Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing CapabilitiesGlobeNewsWire • 11/14/24
Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary DiseaseGlobeNewsWire • 11/08/24
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024GlobeNewsWire • 10/14/24
Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated PathogensGlobeNewsWire • 07/31/24
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial PneumoniaGlobeNewsWire • 07/18/24
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.GlobeNewsWire • 09/21/23
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/SGlobeNewsWire • 09/18/23
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/SGlobeNewsWire • 09/12/23
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo HoldingsGlobeNewsWire • 09/07/23
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point CapitalPRNewsWire • 08/23/23
Investor Alert: Abbott Cooper PLLC Announces Investigation into Paratek Pharmaceuticals, Inc.; Urges Paratek Stockholders to Contact Abbott Cooper Regarding Their Legal RightsBusiness Wire • 08/09/23
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/03/23
Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 MillionGlobeNewsWire • 08/03/23
Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo HoldingsGlobeNewsWire • 08/02/23
NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point CapitalPRNewsWire • 07/11/23
Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary AnthraxGlobeNewsWire • 07/10/23
European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseGlobeNewsWire • 06/27/23
NexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point CapitalPRNewsWire • 06/27/23
PRTK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Paratek Pharmaceuticals, Inc. Is Fair to ShareholdersBusiness Wire • 06/11/23
Shareholder Alert: Ademi LLP investigates whether Paratek Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Gurnet Point Capital and Novo HoldingsPRNewsWire • 06/08/23
Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo HoldingsGlobeNewsWire • 06/06/23
